The present invention provides an anti-cancer drug containing naphthoquinone compound, and more particularly, to an anti-cancer drug containing naphthoquinone compounds of formula (1) and formula (2). The anti-cancer drug of the present invention has low toxicity and excellent anti-cancer activity. In formula (1) R1 and R5 are same or different and are each selected from the group consisting of hydrogen; hydroxy; alkoxy having from 1 to 10 carbons; alkyl having from 1 to 10 carbons; ester having from 1 to 10 carbons; and alkene having from 1 to 10 carbons. In formula (2) R1 and R2 are same or different and are each selected from the group consisting of hydrogen; hydroxy; primary amine; secondary amine; tertiary amine; carboxylic acid; alkoxy having from 1 to 10 carbons; alkyl having from 1 to 10 carbons; ester having from 1 to 10 carbons; and alkene having from 1 to 10 carbons; and R3 et R5 are same or different and are each selected from the group consisting of hydrogen; hydroxy; alkoxy having from 1 to 10 carbons; alkyl having from 1 to 10 carbons; ester having from 1 to 10 carbons; and alkene having from 1 to 10 carbons.